News
HROWM
26.00
+0.39%
0.10
HARROW INC - KLARITY-C PATIENTS TO ACCESS VEVYE FOR $59 PER BOTTLE
Reuters · 3d ago
Weekly Report: what happened at HROWM last week (0331-0404)?
Weekly Report · 6d ago
Weekly Report: what happened at HROWM last week (0324-0328)?
Weekly Report · 03/31 10:03
Harrow: When Cheaper Doesn't Mean Attractive (Rating Upgrade)
Seeking Alpha · 03/29 20:30
Harrow Inc.: Roll The Dice For Strong Upside Prospects As Earnings Ramp
Seeking Alpha · 03/28 17:39
Harrow Inc reports results for the quarter ended December 31 - Earnings Summary
Reuters · 03/27 22:28
Based on the provided financial report articles, I generated the title for the article: **"Eton Pharmaceuticals, Inc. (0001360214) Annual Report for the Fiscal Year Ended December 31, 2024"** Please note that the title may not be exact, as the provided text appears to be a financial report with various sections and data. If you'd like me to generate a more specific title based on the content, please let me know!
Press release · 03/27 20:31
HARROW INC: Q4 EPS $0.40
Reuters · 03/27 20:01
HARROW ANNOUNCES FOURTH-QUARTER AND YEAR-END 2024 AUDITED FINANCIAL RESULTS
Reuters · 03/27 20:01
HARROW INC - TRIESENCE ELIGIBLE FOR SEPARATE REIMBURSEMENT IN ASC AND HOPD SETTINGS FROM APRIL 2025
Reuters · 03/24 11:02
Weekly Report: what happened at HROWM last week (0317-0321)?
Weekly Report · 03/24 09:58
BUZZ-U.S. STOCKS ON THE MOVE-Aditxt, Natgas companies, DocuSign
Reuters · 03/18 17:47
HARROW INC SHARES UP 29.6% AFTER Q4 REVENUE BEAT
Reuters · 03/18 13:35
BUZZ-Harrow jumps on predicting Q4 sales above estimate
Reuters · 03/18 09:30
HARROW INC: QTRLY REV $65 MLN - $67 MLN
Reuters · 03/17 20:03
HARROW INC <HROW.O> Q4 REV VIEW $58.4 MLN -- LSEG IBES DATA
Reuters · 03/17 20:03
Weekly Report: what happened at HROWM last week (0310-0314)?
Weekly Report · 03/17 10:03
HARROW EXECUTES FIVE-YEAR STRATEGIC SUPPLY AND DEVELOPMENT AGREEMENT FOR TRIESENCE®
Reuters · 03/11 11:00
HARROW INC - DEVELOPING NEXT-GENERATION TRIESENCE, TARGETING NDA SUBMISSION TO FDA BY END OF 2027
Reuters · 03/11 11:00
Weekly Report: what happened at HROWM last week (0303-0307)?
Weekly Report · 03/10 10:04
More
Webull provides a variety of real-time HROWM stock news. You can receive the latest news about Harrow Health Inc through multiple platforms. This information may help you make smarter investment decisions.
About HROWM
More
Harrow, Inc. is an eyecare pharmaceutical company. The Company is engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the United States market. It provides a comprehensive portfolio of prescription and non-prescription pharmaceutical products. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America, all of which are marketed under the Harrow name. It owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. It owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, ZERVIATE, and others. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms. IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3% is a low-viscosity gel indicated for ocular surface anesthesia.